Open Nav

Monarch Biosciences, Inc.

  • Colin Kealey, Monarch Biosciences

Increase investor awareness

  • Date:Thursday, October 18
  • Time:9:15 AM - 9:30 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:MonarchBio is a life sciences company focused on commercializing next generation cell therapy and regenerative medicine products based on its Thin Film Nitinol (TFN) technology platform. MonarchBio's lead product, developed in collaboration with the Fred Hutchinson Cancer Research Center, is a unique platform for local delivery of cell therapies treating solid tumors. The so-called Engineered Lymph Node (ELN) uses a bioactive thin film mesh to deliver cell therapies directly to the site of the tumor. Pre-clinical testing of this approach at Fred Hutch has demonstrated significant efficacy advantages in 5 different animal models of solid tumors. MonarchBio believes that the ELN solves some of the key challenges for cell therapies in solid tumors by delivering ultra-high cell densities directly to the tumor, and then providing a stimulatory micronenvironment to encourage proliferation of the engineered cells and sustained tumor killing.
  • Company
  • Company HQ City:Los Angeles
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :Engineered Lymph Node - Cell Therapies for Solid Tumors
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:MonarchBio is currently seeking investors and strategic partners to facilitate clinical trials of its ELN technology. MonarchBio is pursuing a dual approach of partnering assets, while simultaneously developing in-house therapies for commercialization. Ultimately, MonarchBio intends to clinically develop and commercialize a portfolio of products based on its unique Thin Film Nitinol (TFN) biomaterial platform.
  • Total Amount Raised to Date, In All Rounds:$5m
Colin Kealey
Monarch Biosciences